Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140  USA

Tel. +1.617.945.5576 | Email: info@unumrx.com

  • LinkedIn - White Circle
  • Twitter - White Circle

© Copyright 2014-2019 Unum Therapeutics

September 21, 2016

 

Unum Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

 

CAMBRIDGE, MA, September 21, 2016 – Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that President and Chief Executive Officer Chuck Wilson will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on September 29, 2016 at 12:30 pm ET. The conference is being held September 28-29, 2016 at the Lotte New York Palace in New York. 

 

Unum Therapeutics

Unum uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. The Company’s lead program, which combines Unum’s proprietary Antibody-Coupled T-cell Receptor (ACTR) technology with rituximab, is in Phase 1 clinical testing to assess its safety and efficacy. The company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com.

 

# # #